Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Liabilities from Discontinued Operations (2023)

Historic Liabilities from Discontinued Operations for Seres Therapeutics (MCRB) over the last 1 years, with Q4 2023 value amounting to $109.4 million.

  • Seres Therapeutics' Liabilities from Discontinued Operations changed N/A to $109.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $109.4 million, marking a year-over-year change of. This contributed to the annual value of $109.4 million for FY2023, which is N/A changed from last year.
  • Seres Therapeutics' Liabilities from Discontinued Operations amounted to $109.4 million in Q4 2023.
  • In the past 5 years, Seres Therapeutics' Liabilities from Discontinued Operations ranged from a high of $109.4 million in Q4 2023 and a low of $109.4 million during Q4 2023